| Description | Human SLC9A3R2 (NHERF-2/SIP-1) knockout HeLa Ohin cell line is edited by our special CRISPR/Cas9 technology. HeLa Ohio cell line is derived from human negroid cervix carcinoma and is used in tumourigenicity and virus studies. |
| Size | 1 vial (2*106 cells/vial) |
| Parental Cell Line | HeLa Ohin |
| Biosafety Level | 2 |
| Format | Frozen |
| Culture Conditions | Cultured at 37°C with 5% CO2. |
| Culture Medium | EMEM (EBSS) + 2mM Glutamine + 1% Non Essential Amino Acids (NEAA) + 10% Fetal Bovine Serum (FBS) |
| Subculture Conditions | Split confluent cultures 1:5 to 1:10 i.e. seeding at 1-2*10,000 cells/cm2 using 0.25% trypsin or trypsin/EDTA |
| Knockout Validation | Sanger Sequencing |
| Viability | >95% viability before freezing. |
| Adherent /Suspension | Adherent |
| Disease | Negroid cervix carcinoma |
| Purity | Immunogen affinity purified |
| Storage | ˆ’196 ℃ |
| Sterility | All cells test negative for bacteria, yeast, and fungi. |
| Shipping Info | Dry Ice |
| Species | Human |
| Tested Applications | Suitable for: ICC, WB |
| Tissue | Cervix |
| Recommended Control | Human wild-type HeLa Ohin cell line |
| Morphology | Epithelial |
| Pathogens | HIV: Negative Hepatitis B: Negative Hepatitis C: Negative |
| Karyotypic Information | Aneuploid |
| Applications | Tumourigenicity and virus studies |
| Product Type | Knockout Stable Cell Line |
| Price | Inquiry |
